Martha Rueda, MD
Family Medicine · Little Rock, ARNPI 1962607457
Payments from drug & device makers
Across 466 payments — averaging $14.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AbbVie$1K
- Lilly USA, LLC$606
- Novo Nordisk$563
- Pfizer$560
- Amgen$329
- plus $2K from 35 others
What the payments were for
- Food & beverage$6,792100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 88 | $1,182 |
| AbbVie(2 entities) | 62 | $1,068 |
| Lilly USA, LLC | 53 | $606 |
| Novo Nordisk | 36 | $563 |
| Pfizer | 45 | $560 |
| Amgen | 22 | $329 |
| Astellas Pharma US Inc | 17 | $307 |
| Merck | 14 | $205 |
| Biohaven Pharmaceuticals, Inc. | 14 | $182 |
| Corium, LLC | 7 | $161 |
| Biohaven Pharmaceutical Holding Company Ltd. | 12 | $154 |
| Supernus Pharmaceuticals, Inc. | 7 | $139 |
| Boehringer Ingelheim | 8 | $129 |
| AstraZeneca | 9 | $127 |
| Antares Pharma, Inc. | 5 | $92 |
| Sanofi Pasteur Inc. | 6 | $88 |
| Teva Pharmaceuticals USA, Inc. | 7 | $87 |
| Abbott | 4 | $81 |
| Eisai Inc. | 6 | $77 |
| Boston Scientific | 4 | $59 |
| Phathom Pharmaceuticals, Inc. | 4 | $57 |
| Tris Pharma Inc | 3 | $52 |
| Exact Sciences | 3 | $47 |
| Johnson & Johnson | 3 | $43 |
| Sanofi-aventis U.S. LLC | 2 | $41 |
| Bausch Health US, LLC | 2 | $40 |
| Amarin Pharma, Inc. | 3 | $37 |
| Gilead | 3 | $36 |
| Kaleo, Inc. | 2 | $31 |
| Kowa Pharmaceuticals America, Inc. | 2 | $27 |
| Esperion Therapeutics, Inc. | 2 | $27 |
| Seqirus USA Inc | 1 | $18 |
| Halozyme Inc | 1 | $18 |
| Organon | 2 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Collegium Pharmaceutical, Inc. | 1 | $16 |
| Novartis | 1 | $16 |
| Shire North American Group Inc | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Dexcom, Inc. | 1 | $14 |
| BD | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$102
How this compares
$6,792 in reported general payments places this provider in the 90th percentile of 1,347 family medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 50 | $47,024 |
| JardianceEmpagliflozin | 32 | $45,326 |
| EliquisApixaban | 29 | $29,000 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 14 | $23,627 |
| MounjaroTirzepatide | 20 | $18,848 |
| BelsomraSuvorexant | 23 | $9,712 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $7,438 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $7,147 |
| VyvanseLisdexamfetamine Dimesylate | 12 | $4,803 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 36 | $4,797 |
| PremarinEstrogens, Conjugated | 13 | $3,120 |
| Gabapentin | 76 | $1,781 |
| Rosuvastatin Calcium | 120 | $1,679 |
| Atorvastatin Calcium | 169 | $1,586 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 52 | $1,479 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Trijardy Xr | $129 | $68,95346 claims |
| Novo NordiskOzempic | $563 | $47,02450 claims |
| PfizerEliquis, Premarin | $560 | $32,12142 claims |
| Lilly USA, LLCMounjaro | $606 | $18,84820 claims |
| MerckBelsomra | $205 | $9,71223 claims |
| AstraZenecaBreztri Aerosphere | $127 | $7,43812 claims |
| GSKTrelegy Ellipta | $1,182 | $7,14711 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $14 | $4,80312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,347 family medicine providers in Arkansas.
Other family medicine in Little Rock
- George KonisLittle Rock$26.6M
- Kevin RobertsLittle Rock$2.5M
- Derek LewisLittle Rock$1.7M
- Senthil RaghavanLittle Rock$496K
- Benny GreenLittle Rock$150K
- Lee NaylesLittle Rock$114K
- Steve SimpsonLittle Rock$34K
- Harold BettonLittle Rock$18K
- Sanjay DassLittle Rock$14K
- Benjamin McDonaldLittle Rock$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.